EGFR and head and neck squamous cell carcinoma: Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor (EGFR), has shown clinical activity when used in addition to radiotherapy for locally advanced SCCHN and also as monotherapy for RM-SCCHN patients who have failed platinum-based chemotherapy [8,9].